Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Antibody in Pre-treated LELC
NCT04430166Phase 2Unknown
- Sponsor
- Guangzhou University of Chinese Medicine
- Start
- Jun 2020
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD-1 Monoclonal Antibody in lymphoepithelioma-like carcinoma (LELC), sponsored by Guangzhou University of Chinese Medicine. Primary endpoint: Progress-free survival at 9 weeks. Status: unknown.
02
Drugs
PD-1 Monoclonal Antibody
03
Conditions
lymphoepithelioma-like carcinoma (LELC)
Beyond the preview
Go deeper on NCT04430166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430166.